HIV感染者におけるアルツハイマー病の治療
David B Clifford1, Tammie L S Benzinger2, Jee-Young Han1
1Department of Neurology Washington University St. Louis Missouri USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 20, 2026
まとめ
抗アミロイド療法 (AAT) は,HIV感染者におけるアルツハイマー病 (AD) の治療において有望であることが示されています. 初期の研究結果は,AATは安全であり,HIV治療に干渉しないことを示しており,HIV感染者の高齢化に希望を与えています.
科学分野:
- 神経学 神経学とは
- 感染症 感染症は感染症です.
- ゲリアトリクス ゲリアトリクス
背景:
- 近代的なヒト免疫不全ウイルス (HIV) 治療法により,個人は長生きし,高齢化に至ります.
- 一般的な神経変性疾患であるアルツハイマー病 (AD) は,抗アミロイド療法 (AAT) で治療することができます.
- HIV陽性の個人はAAT臨床試験から除外され,この集団における安全性および有効性データは不明のまま残されました.
研究 の 目的:
- HIVがよくコントロールされている個体におけるAATの安全性と有効性を評価する.
- 進行中のHIV治療に対するAATの影響を評価する.
主な方法:
- HIV感染者におけるADの10年間の進行を詳細に記述した症例報告.
- 総合的な臨床評価とバイオマーカー分析を活用しました.
- AATの投与とそのHIV管理に対する効果を文書化しました.
主要な成果:
- ADの診断は,一貫した臨床的およびバイオマーカーの証拠によって確認されました.
- AATは,報告された合併症なしで投与されました.
- HIV治療は,研究期間中ずっと効果的でした.
結論:
- このケースは,HIV感染者におけるAATの安全な使用に関する最初の証拠を提供します.
- AATはHIV治療に悪影響を及ぼさないようです.
- 発見は,ADを発症するかもしれない高齢のHIV感染者集団の増加に関連しています.
関連する概念動画
Retrovirus Life Cycles
43.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42


